Background: Dengue is a disease caused by a virus transmitted by mosquitoes in tropical and subtropical regions. Dengue is a leading cause of hospital stays and death in parts of Asia and Latin America, and outbreaks have occurred in the US. Currently, dengue vaccines are limited and do not protect all people equally. One vaccine actually increased the risk of severe disease in some people and was taken off the market. Better vaccines are needed. Objectives: To test a potential new vaccine against dengue. To see if side effects and immune responses are different depending on a person's previous exposure to dengue. Eligibility: Healthy people aged 18 to 59 years. Design: Participants will visit the clinic 11 times in 7 months; 9 of those visits will be in the first 2 months. Two additional visits are optional. Participants will be screened. They will have a physical exam with urine and blood tests. They will complete a survey about their travel history. Participants may opt to have a lymph node aspiration before receiving the study vaccine. An area in the left armpit will be numbed. A needle will be inserted to remove some cells from a lymph node. The vaccine will be injected into the fat under the skin of the participant's upper left arm. Participants will return for a provider visit and blood draws every 3 days for about the first 2 weeks. Then they will return for a provider visit and blood draws after longer intervals up to 7 months. The lymph node aspiration may be repeated at later visits. Participants may opt to return for a last visit after 12 months.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Local Adverse Events (AEs)
Timeframe: Through day 28 after vaccine administration
Number of Participants With Systemic Adverse Events (AEs)
Timeframe: Through day 28 after vaccine administration
Severity of Local Adverse Events (AEs) by Grade
Timeframe: Through day 28 after vaccine administration
Severity of Systemic Adverse Events (AEs)
Timeframe: Through day 28 after vaccine administration
Number of Participants With Unexpected Adverse Events (AEs)
Timeframe: Through day 28 after vaccine administration
Number of Participants With Serious Adverse Events (AEs)
Timeframe: Through day 180 after vaccine administration
Mean Fold-change in Dengue virus1-4 Neutralizing Antibody Mean Titer Between Days 0 and 28
Timeframe: Day 28 and day 0
Mean Peak Viremia
Timeframe: Day 3 through day 15